These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 31933254)

  • 1. Artificial Intelligence Within Pharmacovigilance: A Means to Identify Cognitive Services and the Framework for Their Validation.
    Mockute R; Desai S; Perera S; Assuncao B; Danysz K; Tetarenko N; Gaddam D; Abatemarco D; Widdowson M; Beauchamp S; Cicirello S; Mingle E
    Pharmaceut Med; 2019 Apr; 33(2):109-120. PubMed ID: 31933254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Artificial Intelligence and the Future of the Drug Safety Professional.
    Danysz K; Cicirello S; Mingle E; Assuncao B; Tetarenko N; Mockute R; Abatemarco D; Widdowson M; Desai S
    Drug Saf; 2019 Apr; 42(4):491-497. PubMed ID: 30343417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Training Augmented Intelligent Capabilities for Pharmacovigilance: Applying Deep-learning Approaches to Individual Case Safety Report Processing.
    Abatemarco D; Perera S; Bao SH; Desai S; Assuncao B; Tetarenko N; Danysz K; Mockute R; Widdowson M; Fornarotto N; Beauchamp S; Cicirello S; Mingle E
    Pharmaceut Med; 2018; 32(6):391-401. PubMed ID: 30546259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Artificial Intelligence" for Pharmacovigilance: Ready for Prime Time?
    Ball R; Dal Pan G
    Drug Saf; 2022 May; 45(5):429-438. PubMed ID: 35579808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse Drug Reaction Case Safety Practices in Large Biopharmaceutical Organizations from 2007 to 2017: An Industry Survey.
    Stergiopoulos S; Fehrle M; Caubel P; Tan L; Jebson L
    Pharmaceut Med; 2019 Dec; 33(6):499-510. PubMed ID: 31933240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Will the future of pharmacovigilance be more automated?
    Salvo F; Micallef J; Lahouegue A; Chouchana L; Létinier L; Faillie JL; Pariente A
    Expert Opin Drug Saf; 2023; 22(7):541-548. PubMed ID: 37435796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What place for intelligent automation and artificial intelligence to preserve and strengthen vigilance expertise in the face of increasing declarations?
    Pariente A; Micallef J; Lahouegue A; Molimard M; Auffret M; Chouchana L; Denis B; Faillie JL; Grandvuillemin A; Letinier L; Pierron E; Pons C; Pujade I; Rubino H; Salvo F
    Therapie; 2023; 78(1):131-143. PubMed ID: 36572627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trust but Verify: Lessons Learned for the Application of AI to Case-Based Clinical Decision-Making From Postmarketing Drug Safety Assessment at the US Food and Drug Administration.
    Ball R; Talal AH; Dang O; Muñoz M; Markatou M
    J Med Internet Res; 2024 Jun; 26():e50274. PubMed ID: 38842929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing Pharmacovigilance in Sub-Saharan Africa Through Training and Mentoring: A GSK Pilot Initiative in Malawi.
    Jusot V; Chimimba F; Dzabala N; Menang O; Cole J; Gardiner G; Ofori-Anyinam O; Oladehin O; Sambakunsi C; Kawaye M; Stegmann JU; Guerra Mendoza Y
    Drug Saf; 2020 Jun; 43(6):583-593. PubMed ID: 32239447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of Artificial Intelligence to Support the Automatic Coding of Patient Adverse Drug Reaction Reports, Using Nationwide Pharmacovigilance Data.
    Martin GL; Jouganous J; Savidan R; Bellec A; Goehrs C; Benkebil M; Miremont G; Micallef J; Salvo F; Pariente A; Létinier L;
    Drug Saf; 2022 May; 45(5):535-548. PubMed ID: 35579816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Machine Learning Approach with Human-AI Collaboration for Automated Classification of Patient Safety Event Reports: Algorithm Development and Validation Study.
    Chen H; Cohen E; Wilson D; Alfred M
    JMIR Hum Factors; 2024 Jan; 11():e53378. PubMed ID: 38271086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorting Through the Safety Data Haystack: Using Machine Learning to Identify Individual Case Safety Reports in Social-Digital Media.
    Comfort S; Perera S; Hudson Z; Dorrell D; Meireis S; Nagarajan M; Ramakrishnan C; Fine J
    Drug Saf; 2018 Jun; 41(6):579-590. PubMed ID: 29446035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Use of Artificial Intelligence in Pharmacovigilance: A Systematic Review of the Literature.
    Salas M; Petracek J; Yalamanchili P; Aimer O; Kasthuril D; Dhingra S; Junaid T; Bostic T
    Pharmaceut Med; 2022 Oct; 36(5):295-306. PubMed ID: 35904529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacovigilance in Israel - tools, processes, and actions.
    Schwartzberg E; Berkovitch M; Dil Nahlieli D; Nathan J; Gorelik E
    Isr J Health Policy Res; 2017 Aug; 6(1):29. PubMed ID: 28760141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Artificial Intelligent Context-Aware Machine-Learning Tool to Detect Adverse Drug Events from Social Media Platforms.
    Roosan D; Law AV; Roosan MR; Li Y
    J Med Toxicol; 2022 Oct; 18(4):311-320. PubMed ID: 36097239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Artificial Intelligence in Pharmacovigilance: Scoping Points to Consider.
    Hauben M; Hartford CG
    Clin Ther; 2021 Feb; 43(2):372-379. PubMed ID: 33478803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Making Sense of Pharmacovigilance and Drug Adverse Event Reporting: Comparative Similarity Association Analysis Using AI Machine Learning Algorithms in Dogs and Cats.
    Xu X; Mazloom R; Goligerdian A; Staley J; Amini M; Wyckoff GJ; Riviere J; Jaberi-Douraki M
    Top Companion Anim Med; 2019 Dec; 37():100366. PubMed ID: 31837760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacovigilance activities in ASEAN countries.
    Suwankesawong W; Dhippayom T; Tan-Koi WC; Kongkaew C
    Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1061-9. PubMed ID: 27174034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing an Artificial Intelligence-Guided Signal Detection in the Food and Drug Administration Adverse Event Reporting System (FAERS): A Proof-of-Concept Study Using Galcanezumab and Simulated Data.
    Al-Azzawi F; Mahmoud I; Haguinet F; Bate A; Sessa M
    Drug Saf; 2023 Aug; 46(8):743-751. PubMed ID: 37300636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards Automating Adverse Event Review: A Prediction Model for Case Report Utility.
    Muñoz MA; Dal Pan GJ; Wei YJ; Delcher C; Xiao H; Kortepeter CM; Winterstein AG
    Drug Saf; 2020 Apr; 43(4):329-338. PubMed ID: 31912439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.